ASCO 2019 | Patient-reported outcomes with CAR T-cell therapy
Surbhi Sidana
Surbhi Sidana, MD, of the Mayo Clinic, Rochester, MN, talks about patient-reported outcomes (PROs) for patients undergoing CAR T-cell therapy at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.
Similar topics
Related videos

Venetoclax monotherapy for relapsed/refractory Waldenström’s macroglobulinemia
Jorge Castillo

Waldenström's PFS unaffected by ibrutinib dose reduction, for now
Jorge Castillo

Anti-CD19 CAR T-cell therapy in combination with ibrutinib for CLL/SLL
Saar Gill

An exciting era for CAR T-cell therapy
Mohamad Mohty

Ibrutinib combinations for CLL: iLLUMINATE results & more
Carol Moreno
More from Surbhi Sidana